Imunon, Inc. (NASDAQ:IMNN) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET

Company Participants

Kim Golodetz - Investor Relations

Corinne Le Goff - President and Chief Executive Officer

Jeffrey Church - Chief Financial Officer

Khursheed Anwer - Chief Science Officer

Nicholas Borys - Chief Medical Officer

Conference Call Participants

Emily Bodnar - H.C. Wainwright & Co, LLC

James Molloy - Alliance Global Partners

David Bautz - Zacks Small-Cap Research

Operator

Good morning. My name is Marliese, and I will be your operator today. At this time, I would like to welcome you to Imunon's Third Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers' prepared remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Kim Golodetz Investor Relations representative. Please go ahead.

Kim Golodetz

Thank you, and good morning, everyone. This is Kim Golodetz with LHA. Welcome to Imunon's Third Quarter 2022 Financial Results and Business Update Conference Call. As has been Imunon's practice and as noted by the operator, prepared remarks will be followed by a question-and-answer session. During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by terminologies such as, expects, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements.

In particular, there is significant uncertainty about the duration and impact of the COVID-19 pandemic. This means results could change at any time and the contemplated impact of COVID-19 on Imunon's operations, financial results and outlook is the best estimate based on the information for today's discussion. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, November 14, 2022. Imunon undertakes no obligation to revise or update comments made during this call, except as required by law.

With that said, I would like to turn the call over to Dr. Corinne Le Goff, President and Chief Executive Officer. Corinne?

Corinne Le Goff

Thank you, Kim, and good morning, everyone. Joining me today is Jeffrey Church, our Chief Financial Officer. In addition, Dr. Khursheed Anwer, our Chief Scientific Officer; and Dr. Nicholas Borys, our Chief Medical Officer, will be available during the Q&A session to answer your questions regarding our development programs with PLACCINE or prophylactic vaccine modality and GEN-1, our IL-12 immunotherapy for the treatment of advanced ovarian cancer.